New York, USA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Global Alopecia Treatment Market is Anticipated to Surpass ~USD 4 Billion by 2030 | DelveInsight The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by various factors, as well as increasing research and development efforts in alopecia treatment and management, projected for the 2024 to 2030 forecast period. DelveInsight’s Alopecia Treatment Market Insights report provides the current and forecast market analysis, individual leading alopecia treatment companies’ market shares, challenges, alopecia treatment market drivers, barriers, trends, and key market alopecia treatment companies in the market.
Key Takeaways from the Alopecia Treatment Market Report As per DelveInsight estimates, the North American region is anticipated to dominate the global alopecia treatment market during the forecast period. In the treatment type segment of the alopecia treatment market, the pharmaceuticals category had a significant revenue share in the alopecia treatment market in 2023. Notable alopecia treatment companies such as Pfizer, GlaxoSmithKline plc, Sun Pharmaceuticals Industries Ltd, Dr.
Reddy’s Laboratories Ltd, Freedom Laser Therapy, Apira Science Inc., Lutronic, Theradome, Revian Inc., Lexington Intl.
, LLC, and several others, are currently operating in the alopecia treatment market. In July 2024 , the FDA approved Sun Pharmaceutical's oral janus kinase (JAK) inhibitor.
